DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma

Information source: Hospital Sirio-Libanes
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis; Hepatocellular Carcinomas

Intervention: Low intensity amplitude-moduled electromagnetic fields (Device)

Phase: N/A

Status: Active, not recruiting

Sponsored by: Hospital Sirio-Libanes

Official(s) and/or principal investigator(s):
Frederico P Costa, MD, Principal Investigator, Affiliation: Hospital Sirio-Libanes

Summary

The propose of this study is to identification of a group of specific amplitude-modulated frequencies of low intensity electromagnetic fields that is associated with biofeedback upon exposure to in patients with hepatitis B carries with or without hepatocellular carcinoma.

Clinical Details

Official title: Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Diagnostic

Primary outcome: Identification of different group of specific frequencies of modulation in hepatitis B carriers with and without hepatocellular carcinoma associated with biofeedback response

Secondary outcome: Characterization of differences biofeedback response in hepatitis B carriers with and without hepatocellular carcinoma

Detailed description: Patients will be exposed by different specific amplitude-modulated frequencies of low intensity electromagnetic fields for 30 min. During the exposure, autonomic response with be recorded in order to identify biofeedback response. Differences in group of frequencies is expected in patients with hepatitis B carries with or without hepatocellular carcinoma.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- hepatitis B carriers patients

- hepatitis B carriers patients with hepatocellular cancer patients

Exclusion Criteria:

- other tumor types

- other hepatitis types

Locations and Contacts

Hospital Sírio Libanês, São Paulo 01308-050, Brazil
Additional Information

Results of a phase II study on patients with hepatocellular carcinoma

Starting date: April 2012
Last updated: June 12, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017